These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 15086725)

  • 1. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
    Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
    Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
    Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
    Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
    Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
    Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
    Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
    Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
    Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
    Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
    Skírnisdóttir I; Seidal T
    Oncol Rep; 2012 Mar; 27(3):741-7. PubMed ID: 22159712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
    Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
    Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths.
    Alshenawy HA
    Ann Diagn Pathol; 2010 Dec; 14(6):387-95. PubMed ID: 21074685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
    Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
    Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
    Skirnisdottir I; Seidal T
    Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
    Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.